Overall, available preclinical and clinical data suggest HBI-8000 play significant roles in cancer therapy, either as monotherapy in ATL and PTCL or in combination with mainstay treatment, such as immune CPIs or aromatase inhibitors, in solid tumors. The gene discussed is CYP19A1; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.